CytoMed Therapeutics Signs At-the-Market Sales Agreement

TL;DR

CytoMed inked an ATM deal with R.F. Lafferty to sell shares.

AI Summary

On August 18, 2025, CytoMed Therapeutics Limited entered into an at-the-market sales agreement with R.F. Lafferty & Co., Inc. as sales agent. This agreement allows the company to offer and sell its ordinary shares from time to time through the agent.

Why It Matters

This agreement provides CytoMed Therapeutics with a flexible way to raise capital by selling its shares on the open market as needed.

Risk Assessment

Risk Level: medium — At-the-market agreements can lead to dilution for existing shareholders if shares are sold at unfavorable prices.

Key Players & Entities

• CytoMed Therapeutics Limited (company) — Company entering into the agreement
• R.F. Lafferty & Co., Inc. (company) — Sales agent for the agreement
• August 18, 2025 (date) — Date the agreement was entered into

FAQ

Key Financial Figures

• $4,304,945 — he Company may offer and sell up to U.S.$4,304,945 of Shares. Under the Sales Agreement,

Filing Documents

• form6-k.htm (6-K) — 16KB
• ex5-1.htm (EX-5.1) — 86KB
• ex10-1.htm (EX-10.1) — 288KB
• ex99-1.htm (EX-99.1) — 12KB
• ex99-1_001.jpg (GRAPHIC) — 9KB
• 0001641172-25-024695.txt ( ) — 416KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-41677 CytoMed Therapeutics limited (Translation of registrant’s name into English) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Entry into a Material Definitive Agreement. On August 18, 2025, CytoMed Therapeutics Limited. (the “Company”), a company incorporated in Singapore, entered into an at-the-market sales agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), as sales agent, pursuant to which the Company may offer and sell, from time to time through the Agent, ordinary shares, no par value, of the Company (the ordinary shares to be sold pursuant to the Sales Agreement, the “Shares”). The offer and sale of the Shares, if any, will be made pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-288033), which was initially filed with the United States Securities and Exchange Commission (the “Commission”) on June 13, 2025, and was declared effective, as amended, by the Commission on June 23, 2025 and as supplemented by the prospectus supplement, dated August 18, 2025 relating to the Shares which may be issued from time to time pursuant to the Sales Agreement, (the “Prospectus Supplement”). Pursuant to the Prospectus Supplement, the Company may offer and sell up to U.S.$4,304,945 of Shares. Under the Sales Agreement, subject to the terms of the placement notice defined in the Sales Agreement, the Agent may sell Placement Shares by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on the Exchange, on any other existing trading market for the Ordinary Shares or to or through a market maker. The Company is not obligated to make any sales of Shares under the Sales Agreement and no assurance can be given that it will sell any Shares under the Sales Agreement, or, if it does, as to the price or number of Shares that it will sell, or the dates on which any such sales will take place. The aggregate compensation payable to the Agent as sales agent is equal to 2.5% of the aggregate gross proceeds from each Placement Shares sold pursuant to the Sales Agreement. The Sales Agreement may be terminated by either party as set forth in the Sales Agreement. In addition, the Company has agreed in the Sales Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act. The foregoing is not a complete description of the Sales Agreement and is qualified by reference to the full text and terms of the Sales Agreement, which is filed as Exhibit 10.1 to this current report and incorporated herein by reference. The Company plans to use the net proceeds from this offering for general corporate purposes, including business diversification and development initiatives, and capital expenditures. The Company may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies. However, as of the date of this report, the Company has not entered into any definitive agreements. On August 18, 2025, the Company issued a press release entitled “CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program.” A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 6-K. General The information contained in this Report on Form 6-K of the Company, are hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-288033) and Registration Statement on Form S-8 (File No. 333-284145). Exhibit Index Exhibit No. 5.1 Opinion of Opal Lawyers LLC 10.1 Sales Agreement, dated August 18, 2025, by and between CytoMed Therapeutics Limited and R.F. Lafferty & Co., Inc. 23.1 Consent of Opal Lawyers LLC (included in Exhibit 5.1) 99.1 Press Release - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CytoMed Therapeutics Limited Date: August 18, 2025 By: /s/ Choo Chee Kong Name: Choo Chee Kong Title: Chairman and Director

View Full Filing

View this 6-K filing on SEC EDGAR